Similar articles

• [Behavior of serum triglycerides, cholesterol, uric acid and sugar levels and of thrombocyte function in heart infarct patients during a 2-year therapy with acetylsalicylic acid, placebo or phenprocoumon].

  Weber E, Walter E, Pfleiderer T. Weber E, et al. Verh Dtsch Ges Inn Med. 1977 Apr 17-21;83:1731-5. Verh Dtsch Ges Inn Med. 1977. PMID: 347797 Clinical Trial. German. No abstract available.
• [Course control of platelet function and blood lipid levels during a 2 years prospective study on the prevention of reinfarction with acetylsalicylic acid, phenprocoumon and placebo].

  Walter E, Weber E, Loew D. Walter E, et al. Verh Dtsch Ges Inn Med. 1978;(84):1481-5. Verh Dtsch Ges Inn Med. 1978. PMID: 369187 Clinical Trial. German. No abstract available.
• Secondary prevention of myocardial infarction. Comparison of acetylsalicylic acid, phenprocoumon and placebo. A multicenter two-year prospective study.

  Breddin K, Loew D, Lechner K, Uberla K, Walter E. Breddin K, et al. Thromb Haemost. 1979 Feb 28;41(1):225-36. Thromb Haemost. 1979. PMID: 483232 Clinical Trial. No abstract available.
• [Acetylsalicylic acid after myocardial infarct].

  Sinzinger H, Kritz H. Sinzinger H, et al. Wien Klin Wochenschr. 1997;109 Suppl 2:25-8. Wien Klin Wochenschr. 1997. PMID: 9340919 Review. German.
• [Platelet antiaggregants or anticoagulants in the secondary prevention after myocardial infarct].

  Di Pasquale G, Ottani F, Ceré E, Biancoli S, Sassone B, Lombardi A. Di Pasquale G, et al. Recenti Prog Med. 1998 Oct;89(10):514-9. Recenti Prog Med. 1998. PMID: 9842255 Review. Italian.